PT Kalbe Farma Tbk (PT Kalbe Farma Tbk) Total Liabilities : $315 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is PT Kalbe Farma Tbk Total Liabilities?

PT Kalbe Farma Tbk's Total Liabilities for the quarter that ended in Mar. 2024 was $315 Mil.

PT Kalbe Farma Tbk's quarterly Total Liabilities declined from Sep. 2023 ($309.68 Mil) to Dec. 2023 ($255.42 Mil) but then increased from Dec. 2023 ($255.42 Mil) to Mar. 2024 ($314.51 Mil).

PT Kalbe Farma Tbk's annual Total Liabilities increased from Dec. 2021 ($308.41 Mil) to Dec. 2022 ($327.00 Mil) but then declined from Dec. 2022 ($327.00 Mil) to Dec. 2023 ($255.42 Mil).

PT Kalbe Farma Tbk Total Liabilities Historical Data

The historical data trend for PT Kalbe Farma Tbk's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Kalbe Farma Tbk Total Liabilities Chart

PT Kalbe Farma Tbk Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

256.04

304.02

308.41

327.00

255.42

PT Kalbe Farma Tbk Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															353.11	375.55	309.68	255.42	314.51

PT Kalbe Farma Tbk Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PT Kalbe Farma Tbk's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	210.377	+	(20.678	+	2.507
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	21.857)
	=	255

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1755.161	-	1499.742
	=	255

PT Kalbe Farma Tbk's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	262.813	+	(27.12	+	2.509
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	22.068)
	=	315

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1878.585	-	1564.075
	=	315

PT Kalbe Farma Tbk Total Liabilities Related Terms

Thank you for viewing the detailed overview of PT Kalbe Farma Tbk's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

PT Kalbe Farma Tbk (PT Kalbe Farma Tbk) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Kalbe Farma Tbk (OTCPK:PTKFY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PTKFF:USA KLBF:Indonesia

Address

Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, Jakarta, IDN, 10510

Website

https://www.kalbe.co.id

Kalbe Farma is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. Majority of the company's gross profits are derived from the distribution and logistics segments. The company primarily operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.

PT Kalbe Farma Tbk (PT Kalbe Farma Tbk) Headlines

No Headlines